CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

NCT05121038 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer
Pancreas Cancer
Digestive Cancer

Interventions

DRUG: CEND-1
DRUG: Panitumumab
DRUG: Folfirinox

Sponsor

Anup Kasi

Collaborators

[object Object]